Cargando…

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Factor VIII (FVIII) circulates in a noncovalent complex with von Willebrand Factor (VWF), the latter determining FVIII half-life. The VWF-binding aptamer rondaptivon pegol (BT200) increases plasma levels of VWF/FVIII in healthy volunteers. This trial assessed its safety, pharmacokinetics, and pharma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ay, Cihan, Kovacevic, Katarina D., Kraemmer, Daniel, Schoergenhofer, Christian, Gelbenegger, Georg, Firbas, Christa, Quehenberger, Peter, Jilma-Stohlawetz, Petra, Gilbert, James C., Zhu, Shuhao, Beliveau, Martin, Koenig, Franz, Iorio, Alfonso, Jilma, Bernd, Derhaschnig, Ulla, Pabinger, Ingrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651782/ https://www.ncbi.nlm.nih.gov/pubmed/36108308 http://dx.doi.org/10.1182/blood.2022016571

Ejemplares similares

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease
por: Ay, Cihan, et al.
Publicado: (2022)

The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial
por: Kovacevic, Katarina D., et al.
Publicado: (2021)

The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin
por: Kovacevic, Katarina D., et al.
Publicado: (2020)

Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status
por: Rejtő, Judit, et al.
Publicado: (2023)

The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients
por: Kovacevic, Katarina D., et al.
Publicado: (2021)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

Defibrotide enhances fibrinolysis in human endotoxemia – a randomized, double blind, crossover trial in healthy volunteers
por: Schoergenhofer, Christian, et al.
Publicado: (2019)

Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing
por: Schoergenhofer, Christian, et al.
Publicado: (2018)

The use of frozen plasma samples in thromboelastometry
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
por: Gelbenegger, Georg, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose‐escalating trial
por: Buchtele, Nina, et al.
Publicado: (2020)

Colistin dampens fibrinolysis and endothelial activation during endotoxaemia: A randomised, double blind trial
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200
por: Zhu, Shuhao, et al.
Publicado: (2020)

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020)

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer
por: Zhu, Shuhao, et al.
Publicado: (2020)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Dissociation between systemic and pulmonary anti‐inflammatory effects of dexamethasone in humans
por: Bartko, Johann, et al.
Publicado: (2016)

Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022)

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study
por: Obermeier, Hanna L., et al.
Publicado: (2019)

A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway
por: Bartko, Johann, et al.
Publicado: (2018)

Evaluation of anti-inflammatory and anti-adhesive effects of heparins in human endotoxemia
por: Derhaschnig, U, et al.
Publicado: (2002)

Desmopressin in nonsevere hemophilia A: patient perspectives on use and efficacy
por: Romano, Lorenzo G.R., et al.
Publicado: (2023)

Micellar Curcumin: Pharmacokinetics and Effects on Inflammation Markers and PCSK‐9 Concentrations in Healthy Subjects in a Double‐Blind, Randomized, Active‐Controlled, Crossover Trial
por: Grafeneder, Juergen, et al.
Publicado: (2022)

P1663: THE EFFECTS OF OBESITY ON BLEEDING FREQUENCY AND PARAMETERS OF FIBRINOLYSIS IN PATIENTS WITH NON-SEVERE HEMOPHILIA
por: Königsbrügge, O., et al.
Publicado: (2022)

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers
por: Hobl, Eva-Luise, et al.
Publicado: (2015)

Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting
por: Ay, Cihan, et al.
Publicado: (2020)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
por: Gelbenegger, Georg, et al.
Publicado: (2019)

Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence
por: Buchtele, Nina, et al.
Publicado: (2018)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Pain management in hemophilia: expert recommendations
por: Stromer, Waltraud, et al.
Publicado: (2021)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Acetylsalicylic acid in critically ill patients: a cross‐sectional and a randomized trial
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta‐Analysis
por: Gelbenegger, Georg, et al.
Publicado: (2021)

P1665: WHOLE-BLOOD ROTATIONAL THROMBOELASTOMETRY (ROTEM) AS A DIAGNOSTIC TOOL IN PATIENTS WITH BLEEDING OF UNKNOWN CAUSE (BUC)
por: Mehic, D., et al.
Publicado: (2022)

Multi-phasic life-threatening anaphylaxis refractory to epinephrine managed by extracorporeal membrane oxygenation (ECMO): A case report
por: Grafeneder, Juergen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1gv9qutu0ncpsb6cjggj7i30d0